For a patient with ascites, should torsemide be used instead of furosemide as the first‑line loop diuretic, and what are the appropriate dosing considerations?

Furosemide Remains the First-Line Loop Diuretic for Ascites in Cirrhosis

For patients with ascites due to cirrhosis, furosemide should be used as the first-line loop diuretic in combination with spironolactone, starting at 40 mg/day and titrating up to 160 mg/day as needed. Torsemide can be considered as a second-line option only in patients who demonstrate inadequate response to furosemide.

Guideline-Based Recommendations

All major hepatology guidelines consistently recommend furosemide as the standard loop diuretic for cirrhotic ascites:

• EASL 2018 guidelines explicitly state: "In patients who do not respond to anti-mineralocorticoids...furosemide should be added at an increasing stepwise dose from 40 mg/day to a maximum of 160 mg/day" 1. Importantly, they note that "Torasemide can be given in patients exhibiting a weak response to furosemide" 1, positioning it clearly as second-line therapy.

• AASLD 2021 guidelines recommend "loop diuretics (e.g., furosemide, torsemide, bumetanide)" but list furosemide first and provide specific dosing for furosemide (40-160 mg/day) 2.

• KASL 2018 guidelines recommend "Furosemide is recommended at a starting dosage of 20-40 mg/day, increasing to 160 mg/day" 3.

• Multiple iterations of hepatology practice guidelines (2004,2009) consistently recommend the spironolactone 100 mg + furosemide 40 mg combination as standard therapy 4, 5.

Dosing Algorithm for Ascites

Initial regimen:

• Spironolactone 100 mg once daily + Furosemide 40 mg once daily (maintaining 100:40 ratio)
• For first episode of grade 2 ascites: Consider spironolactone alone initially 1
• For recurrent or long-standing ascites: Start combination therapy 1, 4

Dose escalation:

• Increase both drugs simultaneously every 3-5 days (or 72 hours) if inadequate response 4, 2
• Maintain the 100 mg:40 mg ratio to preserve normokalemia 4
• Maximum doses: Spironolactone 400 mg/day, Furosemide 160 mg/day 1, 3, 2

When to consider torsemide:

• Only after demonstrating inadequate natriuresis with maximum-dose furosemide 1
• Starting dose: 5-10 mg once daily (per FDA label for hepatic cirrhosis) 6
• Maximum studied dose in cirrhosis: 40 mg/day 1, 6
• Must be given with aldosterone antagonist 6

Why Furosemide Remains Standard

Lack of superiority data: Despite theoretical pharmacokinetic advantages of torsemide (higher bioavailability, longer half-life), clinical outcomes in ascites management are equivalent. The 2001 randomized trial in 46 cirrhotic patients found that while torsemide induced greater 24-hour diuresis, "body weight loss, treatment period, ascites resolution and complications were similar in both groups" 7. This mirrors findings from heart failure literature where the large TRANSFORM-HF trial showed no mortality or hospitalization benefit with torsemide 8, 9.

Established safety profile: Furosemide has decades of safety data in cirrhotic patients. The 2009 Hepatology guidelines note that "the good oral bioavailability of furosemide in the patient with cirrhosis, together with the acute reductions in glomerular filtration rate associated with intravenous furosemide, favor use of the oral route" 4.

Limited evidence in cirrhosis: The FDA label for torsemide explicitly states "Doses higher than 40 mg have not been adequately studied in this population" for hepatic cirrhosis 6. Most torsemide studies in cirrhosis are small (14-20 patients) and short-term 7, 10, 11.

Critical Caveats

Avoid intravenous furosemide in cirrhosis: IV furosemide causes acute reductions in glomerular filtration rate and can precipitate azotemia in cirrhotic patients 4. Oral administration is strongly preferred.

Monitor for hepatic encephalopathy: The FDA label warns that torsemide "can cause sudden alterations of fluid and electrolyte balance which may precipitate hepatic coma in patients with hepatic disease with cirrhosis and ascites. In these patients, diuresis with torsemide is best initiated in the hospital" 6. This same concern applies to all loop diuretics but is specifically highlighted for torsemide.

Mandatory aldosterone antagonist co-administration: When using torsemide in cirrhosis, the FDA label mandates it be "administered together with an aldosterone antagonist or a potassium-sparing diuretic" to prevent hypokalemia and metabolic alkalosis 6.

Target appropriate weight loss: Maximum 0.5 kg/day without peripheral edema, 1 kg/day with edema 1, 3, 2. Faster diuresis risks precipitating renal failure and encephalopathy.

When Torsemide May Be Reasonable

The EASL guideline's recommendation for torsemide in patients with "weak response to furosemide" 1 is supported by pharmacologic data showing torsemide may achieve greater natriuresis in some patients 7, 11. However, this should only be attempted after:

1. Confirming dietary sodium restriction (<2 g/day)
2. Reaching maximum furosemide dose (160 mg/day)
3. Verifying adequate spironolactone dose (400 mg/day)
4. Checking spot urine Na/K ratio to confirm inadequate natriuresis 2

The evidence does not support using torsemide as first-line therapy for ascites. All major guidelines position furosemide as standard, with torsemide reserved for refractory cases. The theoretical pharmacokinetic advantages have not translated into superior clinical outcomes for mortality, ascites resolution, or quality of life in cirrhotic patients.